Compare Adaptive Biotechnologies Corp (ADPT) vs LTC Properties Inc (LTC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs LTC Properties Inc — how do they compare? Adaptive Biotechnologies Corp trades at $25.69 (market cap $4.05B), while LTC Properties Inc trades at $38.12 (market cap $2.12B). The key difference: Adaptive Biotechnologies Corp is the larger of the two by market cap, and LTC Properties Inc pays a 5.78% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | LTC | |
|---|---|---|
Market Cap | $4.05B | $2.12B |
Sector | Health | Real Estate |
52-Week High | $25.45 | $42.81 |
52-Week Low | $12.30 | $33.98 |
Enterprise Value | $4.12B | $2.86B |
Dividend Yield | — | 5.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $24.93, up 5.64% in 24 hours and near its 52-week high. The stock shows bullish technical momentum with improving fundamentals as revenue grew 55% year-over-year to $277M in 2025 while net losses narrowed significantly from -$159M to -$59M. The company's strategic shift to focus on its profitable MRD diagnostics business through a planned separation of Immune Medicine operations has driven investor optimism.
Outlook remains cautiously optimistic as ADPT transitions to a pure-play MRD company with strong gross margins exceeding 75%. While analyst consensus favors Buy ratings (65%), persistent net losses and high valuation multiples (P/S 12.6x, P/B 27.8x) present risks. The $25.50 price target suggests limited upside from current levels amid execution risks.
LTC Properties trades at $39.85, up 1.01% today, with a bullish technical signal supported by moving averages. The REIT shows strong fundamentals with a 14.08 P/E ratio, 38.93% net income margin, and consistent dividend payments of $0.19 monthly. Recent acquisitions in seniors housing (SHOP) portfolio total $285 million year-to-date, driving revenue growth from $210M in 2024 to $263M in 2025. However, earnings misses in two of the last three quarters and rising debt-to-asset ratio to 42.64% warrant caution.
Outlook remains positive due to demographic tailwinds in senior housing and aggressive SHOP expansion, but investors face risks from execution challenges in acquisitions and interest rate sensitivity. Analyst consensus is mixed with 27% buy ratings versus 59% hold, suggesting cautious optimism amid transition phase.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About LTC Properties Inc
LTC Properties Inc is a healthcare facility real estate investment trust. The company operates one segment that works to invest in healthcare facilities through mortgage loans, property lease transactions, and other investments. LTC generates all of its revenue in the United States. LTC is an active capital provider in the seniors housing and health care real estate industry. The company has been actively engaged with its operating partners to create a growing pipeline of projects. LTC considers merger and acquisition investment as a component of its operational growth strategy.
Read more on LTC →
